Exchange Traded Concepts LLC Sells 9,527 Shares of Prestige Consumer Healthcare Inc. $PBH

Exchange Traded Concepts LLC cut its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 43.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 12,410 shares of the company’s stock after selling 9,527 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Prestige Consumer Healthcare were worth $774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in PBH. Wedge Capital Management L L P NC grew its position in Prestige Consumer Healthcare by 29.8% during the third quarter. Wedge Capital Management L L P NC now owns 50,347 shares of the company’s stock valued at $3,142,000 after buying an additional 11,566 shares during the period. Assenagon Asset Management S.A. purchased a new position in Prestige Consumer Healthcare in the third quarter valued at about $1,890,000. Corient Private Wealth LLC grew its position in shares of Prestige Consumer Healthcare by 3.9% during the 2nd quarter. Corient Private Wealth LLC now owns 20,394 shares of the company’s stock valued at $1,628,000 after acquiring an additional 762 shares during the period. Texas Permanent School Fund Corp increased its stake in shares of Prestige Consumer Healthcare by 5.9% during the 2nd quarter. Texas Permanent School Fund Corp now owns 26,949 shares of the company’s stock worth $2,152,000 after purchasing an additional 1,499 shares during the last quarter. Finally, Osaic Holdings Inc. increased its stake in shares of Prestige Consumer Healthcare by 574.5% during the 2nd quarter. Osaic Holdings Inc. now owns 13,226 shares of the company’s stock worth $1,056,000 after purchasing an additional 11,265 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Jeffrey Zerillo sold 719 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $63.67 on Tuesday. The firm has a market capitalization of $3.06 billion, a P/E ratio of 15.80, a PEG ratio of 1.97 and a beta of 0.39. Prestige Consumer Healthcare Inc. has a one year low of $57.25 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. The business has a fifty day moving average price of $60.82 and a 200-day moving average price of $67.00.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The business had revenue of $274.11 million for the quarter, compared to analysts’ expectations of $257.14 million. During the same quarter in the prior year, the firm posted $1.09 EPS. The firm’s quarterly revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on PBH. Jefferies Financial Group lowered their price target on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Oppenheimer decreased their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Wednesday, September 24th. Canaccord Genuity Group decreased their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $85.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).